Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$30.94+2.69%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.30 → 1.32 EPS · FY ending Dec 31, 2027 · 8 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 6 to 8; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for ZYME yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Execute $125 million share repurchase program in 2026 | It has a $125 million share buyback program backed by a stronger balance sheet. | Improving | no meaningful share repurchases executed by end of 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth business with potential value from partnerships, acquisitions, and future royalties, rather than an established earnings compounder. The thesis is in watch status: recent strategic steps are constructive, but financial performance remains weak.
The valuation model indicates a premium versus peers, driven by optionality, meaning value tied to possible future outcomes. The expectations gap is sizable, but model confidence is low and the evidence does not establish that current expectations are justified.
Near term, the elevated risk of another earnings miss reflects a run of recent misses, while reported revenue was much lower year over year in 2026-Q2. Royalty revenue rose from 2026-Q1 to Q2, and the acquisition and collaboration show strategic progress, but delivery on expense discipline and broader revenue growth remains mixed.
Over the next few quarters, the thesis depends on revenue-generating partnerships and acquisitions translating into stronger results, and on zanidatamab approvals supporting royalties or the potential approval milestone. A guidance cut or weaker employment data could add pressure, while continued strength from healthcare bellwethers could support sector momentum; these signals do not resolve ZYME’s company-specific execution risks.
For the 1-to-3-year view, ZYME has strategic progress and measurable early royalty revenue, but weak financial performance and repeated misses keep the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A primary condition in Zymeworks, Inc.'s published investment case. The stated target is reduce adjusted gross operating expenses by ~20% vs 2025. |
| Under Pressure |
| adjusted gross operating expenses do not decline by at least 15% in FY26 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve ~80% revenue growth in 2026 | A primary condition in Zymeworks, Inc.'s published investment case. The stated target is >=80% YoY revenue growth. | Broken | revenue growth falls below 50% in FY26 | Revenue growth: -90.58% FY2026-Q2; GAAP. Published target: >=80% YoY revenue growth. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-90.579978 percent · calculatedLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete strategic acquisition and partnership to strengthen capital | The company completed a $929 million acquisition to support growth and capital needs. | Intact | strategic acquisition or partnership fails to close or provide expected capital support | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$0.28 → $1.32 · observed estimates
$0.19B → $0.35B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $0.28 | $189,777,310 | 5 / 6 |
| 2026-07-25 | $0.28 | $189,777,310 | 5 / 6 |
| 2026-07-26 | $0.28 | $189,777,310 | 5 / 6 |
| 2026-07-27 | $0.96 | $302,024,539 | 5 / 5 |
| 2026-07-28 | $0.96 | $302,024,539 | 5 / 5 |
| 2026-07-29 | $0.51 | $203,943,980 | 5 / 6 |
| 2026-07-30 | $1.08 | $310,524,539 | 5 / 5 |
| 2026-07-31 | $0.51 | $203,943,980 | 5 / 6 |
| 2026-08-01 | $1.23 | $310,524,539 | 5 / 5 |
| 2026-08-02 | $0.83 | $205,977,310 | 5 / 6 |
| 2026-08-03 | $0.83 | $205,977,310 | 5 / 6 |
| 2026-08-04 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-05 | $0.83 | $205,977,310 | 5 / 6 |
| 2026-08-06 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-08 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-09 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-10 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-12 | $1.39 | $363,946,580 | 5 / 6 |
| 2026-08-13 | $1.39 | $363,946,580 | 5 / 6 |
| 2026-08-14 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-15 | $1.31 | $294,210,139 | 5 / 5 |
| 2026-08-16 | $1.31 | $294,210,139 | 6 / 6 |
| 2026-08-17 | $1.31 | $294,210,139 | 6 / 6 |
| 2026-08-18 | $1.31 | $294,210,139 | 6 / 6 |
| 2026-08-19 | $1.31 | $294,210,139 | 6 / 6 |
| 2026-08-20 | $1.01 | $294,669,366 | 6 / 6 |
| 2026-08-21 | $1.01 | $294,669,366 | 6 / 6 |
| 2026-08-22 | $1.01 | $294,669,366 | 6 / 6 |
| 2026-08-23 | $1.01 | $294,669,366 | 6 / 6 |
| 2026-08-24 | $1.01 | $294,669,366 | 6 / 6 |
| 2026-08-25 | $1.01 | $294,669,366 | 6 / 6 |
| 2026-08-26 | $1.22 | $310,448,392 | 6 / 6 |
| 2026-08-27 | $1.22 | $310,448,392 | 6 / 6 |
| 2026-08-28 | $1.22 | $310,448,392 | 6 / 6 |
| 2026-08-29 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-08-30 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-08-31 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-09-01 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-09-02 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-09-03 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-09-04 | $1.30 | $331,697,756 | 6 / 7 |
| 2026-09-05 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-06 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-07 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-08 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-09 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-10 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-11 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-12 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-13 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-14 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-15 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-16 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-17 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-18 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-19 | $1.31 | $333,740,109 | 6 / 7 |
| 2026-09-20 | $1.14 | $323,450,892 | 7 / 7 |
| 2026-09-21 | $1.14 | $323,450,892 | 7 / 7 |
| 2026-09-22 | $1.14 | $323,450,892 | 7 / 7 |
| 2026-09-23 | $1.14 | $323,450,892 | 7 / 7 |
| 2026-09-24 | $1.14 | $323,450,892 | 7 / 7 |
| 2026-09-25 | $1.14 | $321,534,225 | 7 / 7 |
| 2026-09-26 | $1.14 | $321,534,225 | 7 / 7 |
| 2026-09-27 | $1.14 | $321,534,225 | 7 / 7 |
| 2026-09-28 | $1.14 | $321,534,225 | 7 / 7 |
| 2026-09-29 | $1.14 | $321,534,225 | 7 / 7 |
| 2026-09-30 | $1.14 | $321,534,225 | 7 / 7 |
| 2026-10-01 | $1.18 | $343,343,575 | 7 / 7 |
| 2026-10-02 | $1.18 | $343,343,575 | 6 / 7 |
| 2026-10-03 | $1.18 | $343,343,575 | 6 / 7 |
| 2026-10-04 | $1.18 | $343,343,575 | 6 / 7 |
| 2026-10-05 | $1.30 | $343,343,575 | 6 / 7 |
| 2026-10-06 | $1.00 | $345,792,932 | 7 / 7 |
| 2026-10-07 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-08 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-09 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-10 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-11 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-12 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-13 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-14 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-15 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-16 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-17 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-18 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-19 | $1.03 | $345,691,849 | 7 / 7 |
| 2026-10-20 | $1.09 | $345,831,284 | 7 / 8 |
| 2026-10-21 | $1.09 | $345,831,284 | 8 / 8 |
| 2026-10-22 | $1.09 | $345,831,284 | 8 / 8 |
| 2026-10-23 | $1.09 | $345,831,284 | 8 / 8 |
| 2026-10-24 | $1.09 | $345,848,284 | 8 / 8 |
| 2026-10-25 | $1.09 | $349,182,260 | 8 / 8 |
| 2026-10-26 | $1.09 | $349,182,260 | 8 / 8 |
| 2026-10-27 | $1.09 | $349,182,260 | 8 / 8 |
| 2026-10-28 | $1.09 | $349,182,177 | 8 / 8 |
| 2026-10-29 | $1.32 | $353,748,510 | 8 / 8 |
| 2026-10-30 | $1.32 | $353,748,510 | 8 / 8 |
| 2026-10-31 | $1.32 | $353,748,510 | 8 / 8 |
| 2026-11-01 | $1.32 | $353,748,510 | 8 / 8 |
| 2026-11-02 | $1.32 | $353,748,510 | 8 / 8 |
| 2026-11-03 | $1.32 | $353,748,510 | 8 / 8 |
| 2026-11-04 | $1.32 | $353,748,510 | 8 / 8 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 14 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 2 recorded
1 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.